These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 9435414)

  • 21. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The usefulness of thyroid size and TSH receptor antibody (TRAb) determinations in predicting the effectiveness of tiamazole and I-131 treatment for Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):242-7. PubMed ID: 15314993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.
    Uy HL; Reasner CA; Samuels MH
    Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
    Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
    Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
    Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
    J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
    Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
    Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
    J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease.
    Gamstedt A; Wadman B; Karlsson A
    J Clin Endocrinol Metab; 1986 Apr; 62(4):773-7. PubMed ID: 2869050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease.
    Kaise K; Kaise N; Yoshida K; Fukazawa H; Mori K; Yamamoto M; Sakurada T; Saito S; Yoshinaga K
    Endocrinol Jpn; 1991 Aug; 38(4):429-33. PubMed ID: 1687028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
    J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
    Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
    Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.